Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ALT News 25 November 2025 - 31 January 2026

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune, Inc. (NASDAQ: ALT) is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a high-stakes clinical update is expected before year-end, leadership is changing hands, and Wall Street price targets remain dramatically spread out. Shares were indicated around $5.03 early Wednesday, after closing at roughly the same level on Tuesday (Dec. 16). MarketBeat Altimmune stock price action: why traders keep circling ALT ALT has been showing the classic behavior of a catalyst-driven biotech: sharp
17 December 2025
·
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment. Below is a detailed, publication-ready look at today’s ALT stock action , the latest company and clinical news , Wall Street forecasts , and the key catalysts and risks that matter most
12 December 2025
··
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune, Inc. (NASDAQ: ALT) has become a tightly wound biotech story heading into year‑end 2025. The small‑cap developer of liver and metabolic drugs is changing its CEO just weeks before a pivotal 48‑week readout in its lead MASH trial, while Wall Street models still point to triple‑digit upside from today’s share price. As of mid‑day on December 9, 2025, Altimmune stock trades around $5.61 per share, implying a market capitalization of roughly $550 million. Stock Titan That price sits well above its autumn lows but far below analyst targets that cluster in the mid‑teens to high teens. Below is a
9 December 2025
·
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8 and $5.2 per share. INDmoney On Monday, November 24, ALT: According to short‑term technical data, ALT has risen in 6 of the last 10 trading days and is up almost 20% over the past two weeks, as traders reposition ahead
25 November 2025
··

Stock Market Today

American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

7 February 2026
American Airlines shares jumped 7.6% to $15.24 Friday, rebounding with a broad rally that sent the Dow past 50,000 for the first time. Investors are watching the carrier’s battle with United at Chicago O’Hare, where a summer capacity surge could trigger a fare war. American also announced new Philadelphia–Porto service for 2027 and launched a centennial inflight menu.
Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

7 February 2026
Apple closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. The S&P 500 jumped 1.97% and the Nasdaq rose 2.18% as chipmakers rallied, while Amazon fell 5.6% on higher capex guidance. Investors await U.S. jobs data Feb. 11 and CPI Feb. 13. Apple’s next dividend is $0.26 per share, payable Feb. 12.
Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop